Hematopoietic cell transplantation for B-cell lymphoma: an update (Q27026617)

language of work or name

1 reference

July 2012

1 reference

1 reference

19

1 reference

issue

3

1 reference

page(s)

175-86

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

cites work

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Hematopoietic Cell Transplantation for Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

How I treat mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Cancer risk in people infected with human immunodeficiency virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Could bone marrow transplantation cure AIDS?: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481201900302

10.1177/107327481201900302

21 January 2018

Identifiers

DOI

0 references

OpenCitations bibliographic resource ID

3990496

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3990496

PubMed publication ID

22710893

1 reference